PMID- 8781301
OWN - NLM
STAT- MEDLINE
DCOM- 19961018
LR  - 20220310
IS  - 0026-0495 (Print)
IS  - 0026-0495 (Linking)
VI  - 45
IP  - 9
DP  - 1996 Sep
TI  - Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with 
      non-insulin-dependent diabetes mellitus.
PG  - 1130-5
AB  - The safety and efficacy of vanadyl sulfate (VS) was tested in a single-blind, 
      placebo-controlled study. Eight patients (four men and four women) with 
      non-insulin-dependent diabetes mellitus (NIDDM) received VS (50 mg twice daily 
      orally) for 4 weeks. Six of these patients (four men and two women) continued in 
      the study and were given a placebo for an additional 4 weeks. 
      Euglycemic-hyperinsulinemic clamps were performed before and after the VS and 
      placebo phases. VS was associated with gastrointestinal side effects in six of 
      eight patients during the first week, but was well tolerated after that. VS 
      administration was associated with a 20% decrease in fasting glucose 
      concentration (from 9.3 +/- 1.8 to 7.4 +/- 1.4 mmol/L, P < .05) and a decrease in 
      hepatic glucose output (HGO) during hyperinsulinemia (from 5.0 +/- 1.0 pre-VS to 
      3.1 +/- 0.9 micromol/kg x min post-VS, P < .02). The improvement in fasting 
      plasma glucose and HGO that occurred during VS treatment was maintained during 
      the placebo phase. VS had no significant effects on rates of total-body glucose 
      uptake, glycogen synthesis, glycolysis, carbohydrate (CHO) oxidation, or 
      lipolysis during euglycemic-hyperinsulinemic clamps. We conclude that VS at the 
      dose used was well tolerated and resulted in modest reductions of fasting plasma 
      glucose and hepatic insulin resistance. However, the safety of larger doses and 
      use of vanadium salts for longer periods remains uncertain.
FAU - Boden, G
AU  - Boden G
AD  - Division of Endocrinology/Diabetes/Metabolism and the General Clinical Research 
      Center, Temple University Schools of Medicine and Pharmacy, Philadelphia, PA, 
      USA.
FAU - Chen, X
AU  - Chen X
FAU - Ruiz, J
AU  - Ruiz J
FAU - van Rossum, G D
AU  - van Rossum GD
FAU - Turco, S
AU  - Turco S
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Metabolism
JT  - Metabolism: clinical and experimental
JID - 0375267
RN  - 0 (Blood Glucose)
RN  - 0 (Carbohydrates)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Lipids)
RN  - 0 (Placebos)
RN  - 0 (Vanadium Compounds)
RN  - 6DU9Y533FA (vanadyl sulfate)
SB  - IM
MH  - Blood Glucose/analysis
MH  - Carbohydrates/*blood
MH  - Diabetes Mellitus, Type 2/*blood
MH  - Female
MH  - Glucose Clamp Technique
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects/*therapeutic use
MH  - Insulin/blood/metabolism
MH  - Lipids/*blood
MH  - Male
MH  - Middle Aged
MH  - Placebos
MH  - Vanadium Compounds/adverse effects/*therapeutic use
EDAT- 1996/09/01 00:00
MHDA- 1996/09/01 00:01
CRDT- 1996/09/01 00:00
PHST- 1996/09/01 00:00 [pubmed]
PHST- 1996/09/01 00:01 [medline]
PHST- 1996/09/01 00:00 [entrez]
AID - S0026-0495(96)90013-X [pii]
AID - 10.1016/s0026-0495(96)90013-x [doi]
PST - ppublish
SO  - Metabolism. 1996 Sep;45(9):1130-5. doi: 10.1016/s0026-0495(96)90013-x.